Uncategorized
NovaBay reports $4.9 million net loss in second quarter
NovaBay Pharmaceuticals reported a net loss of $4.9 million, or $0.07 per share, in the second quarter compared to a $2.9 million net loss, or $0.06 per share, in the same quarter of 2014, according to a company press release. Total revenue was reported at $1 million for the second quarter, an increase from $123,000 in the same quarter in 2014. The increase was attributed to the commercial launch and sales of Avenova, a treatment for blepharitis, meibomian gland dysfunction and dry eye. From the first to the second quarter, (Read more...)